Factors associated with viral suppression among adults living with HIV on antiretroviral therapy in Nigeria: Analysis of a population-based survey, 2018.
antiretroviral
people living with HIV
survey
viral suppression
Journal
HIV medicine
ISSN: 1468-1293
Titre abrégé: HIV Med
Pays: England
ID NLM: 100897392
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
09
08
2022
accepted:
02
03
2023
medline:
10
7
2023
pubmed:
23
3
2023
entrez:
22
3
2023
Statut:
ppublish
Résumé
Viral load suppression (VLS) is critical in reducing morbidity and mortality associated with HIV as well as minimizing the likelihood of HIV transmission to uninfected persons. The objective of this study was to identify factors associated with VLS among people living with HIV (PLWH) on antiretroviral (ARV) therapy to inform HIV programme strategies in Nigeria. Adult participants, aged 15-64 years, from the 2018 Nigeria HIV/AIDS Indicator and Impact Survey (NAIIS), who self-reported to be a PLWH or had detectable ARVs, were analysed to examine factors associated with VLS defined as HIV RNA <1000 copies/mL. NAIIS measured HIV prevalence, viral load, ARV and hepatitis B in PLWH. Logistic regression models were used and reported weighted prevalence. Of 1322 participants, 949 (68.25%) were women and 1287 (96.82%) had detectable ARVs. The median age was 39.31 [interquartile range (IQR): 31.47-47.63] years. Prevalence of VLS was 80.88%. Compared with participants with detectable ARVs, those with undetectable ARVs in their blood specimens had lower odds of VLS [adjusted odds ratio (aOR) = 0.24, 95% confidence interval (CI): 0.08-0.64). Coinfection with hepatitis B and nonnucleoside reverse transcriptase inhibitor metabolites were also associated with lower odds of VLS. Older people (45-54 vs 15-24 years) had increased odds of VLS (aOR = 2.81, 95% CI: 1.14-6.90). Young people and those with undetectable ARVs had lower odds of virological suppression. Targeted interventions focusing on young people and adherence to medication are needed to achieve the UNAIDS 95-95-95 goals for HIV epidemic control.
Substances chimiques
Reverse Transcriptase Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
827-837Subventions
Organisme : U.S. President's Emergency Plan for AIDS Relief
Informations de copyright
© 2023 British HIV Association.
Références
UNAIDS. Understanding Fast-Track: Accelerating Action to End the AIDS Epidemic by 2030. Published 2015 Accessed December 17, 2020. https://www.unaids.org/en/resources/documents/2015/201506_JC2743_Understanding_FastTrack
Coker M, Etiebet M-A, Chang H, et al. Socio-demographic and adherence factors associated with viral load suppression in HIV-infected adults initiating therapy in northern Nigeria: a randomized controlled trial of a peer support intervention. Curr HIV Res. 2015;13(4):279-285.
Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med. 2000;342(13):921-929. doi:10.1056/nejm200003303421303
Attia S, Egger M, Müller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. Aids. 2009;23(11):1397-1404. doi:10.1097/QAD.0b013e32832b7dca
Cohen MS, Chen YQ, McCauley M, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med. 2016;375(9):830-839. doi:10.1056/nejmoa1600693
Chime OH, Ndibuagu EO, Orji CJ. Rates and predictors of adherence and retention for antiretroviral therapy among HIV-positive adults in Enugu, Nigeria. Malawi Med J. 2019;31(3):204-213. doi:10.4314/mmj.v31i3.7
Okoronkwo I, Okeke U, Chinweuba A, Iheanacho P. Nonadherence factors and sociodemographic characteristics of HIV-infected adults receiving antiretroviral therapy in Nnamdi Azikiwe university teaching hospital, Nnewi, Nigeria. ISRN Aids. 2013;2013:1-8. doi:10.1155/2013/843794
Bijker R, Jiamsakul A, Kityo C, et al. Adherence to antiretroviral therapy for HIV in sub-Saharan Africa and Asia: a comparative analysis of two regional cohorts. J Int AIDS Soc. 2017;20(1):21218. doi:10.7448/IAS.20.1.21218
Federal Ministry of Health Nigeria. Nigeria HIV/AIDS Indicator and Impact Survey (NAIIS) 2018: Technical Report. Abuja, Nigeria 2019.
UNAIDS. AIDSinfo. Published 2020 Accessed September 16, 2020. https://aidsinfo.unaids.org/
Data for Implementation (Data.FI). Improving Viral Load Testing Coverage across USAID-Supported States in Nigeria. Published November 2020 Accessed August 30, 2021. https://datafi.thepalladiumgroup.com/news-and-resources/data-for-action/
UNAIDS. Putting people at the centre brings good results in Nigeria. Published March 2021 Accessed August 30, 2021. https://www.unaids.org/en/resources/presscentre/featurestories/2021/march/20210305_people-at-the-centre-nigeria
Patel HK, Duong YT, Birhanu S, et al. A comprehensive approach to assuring quality of laboratory testing in HIV surveys: lessons learned from the population-based HIV impact assessment project. J Acquir Immune Defic Syndr. 2021;87:S17-S27. doi:10.1097/QAI.0000000000002702
Koal T, Burhenne H, Römling R, Svoboda M, Resch K, Kaever V. Quantification of antiretroviral drugs in dried blood spot samples by means of liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2005;19(21):2995-3001. doi:10.1002/RCM.2158
World Health Organization. Consolidated guidelines on HIV testing services. WHO. Published 2019 Accessed December 16, 2020. https://www.who.int/publications/i/item/978-92-4-155058-1
Foreit KG, Schreiner M. Comparing Alternative Measures of Poverty: Assets-Based Wealth Index vs. Expenditures-Based Poverty Score - MEASURE Evaluation. Published October 2011 Accessed December 16, 2020. https://www.measureevaluation.org/resources/publications/wp-11-123
Stafford KA, Odafe SF, Lo J, et al. Evaluation of the clinical outcomes of the test and treat strategy to implement treat all in Nigeria: results from the Nigeria multi-center ART study. Torpey K, ed. PLoS One. 2019;14(7):e0218555. doi:10.1371/journal.pone.0218555
Badejo O, Noestlinger C, Jolayemi T, et al. Multilevel modelling and multiple group analysis of disparities in continuity of care and viral suppression among adolescents and youths living with HIV in Nigeria. BMJ Glob Heal. 2020;5(11):3269. doi:10.1136/bmjgh-2020-003269
Agaba PA, Meloni ST, Sule HM, et al. Treatment outcomes among older human immunodeficiency virus-infected adults in Nigeria. Open Forum Infect Dis. 2017;4(2):ofx031. doi:10.1093/ofid/ofx031
Tsondai PR, Sohn AH, Phiri S, et al. Characterizing the double-sided cascade of care for adolescents living with HIV transitioning to adulthood across southern Africa. J Int AIDS Soc. 2020;23(1):e25447. doi:10.1002/jia2.25447
Zanoni BC, Mayer KH. The adolescent and young adult HIV cascade of care in the United States: exaggerated health disparities. AIDS Patient Care STDS. 2014;28(3):128-135. doi:10.1089/apc.2013.0345
Nachega JB, Hislop M, Nguyen H, et al. Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa. J Acquir Immune Defic Syndr. 2009;51(1):65-71. doi:10.1097/QAI.0b013e318199072e
Boyes ME, Cluver LD, Meinck F, Casale M, Newnham E. Mental health in south African adolescents living with HIV: correlates of internalising and externalising symptoms. AIDS Care. 2019;31(1):95-104. doi:10.1080/09540121.2018.1524121
Cheng Y, Li X, Lou C, et al. The association between social support and mental health among vulnerable adolescents in five cities: findings from the study of the well-being of adolescents in vulnerable environments. J Adolesc Health. 2014;55(6):S31-S38. doi:10.1016/j.jadohealth.2014.08.020
Laurenzi CA, Skeen S, Gordon S, et al. Preventing mental health conditions in adolescents living with HIV: an urgent need for evidence. J Int AIDS Soc. 2020;23(S5):65-70. doi:10.1002/jia2.25556 23.
Dow DE, Turner EL, Shayo AM, Mmbaga B, Cunningham CK, O'Donnell K. Evaluating mental health difficulties and associated outcomes among HIV-positive adolescents in Tanzania. AIDS Care. 2016;28(7):825-833. doi:10.1080/09540121.2016.1139043
van Wyk BE, Davids LAC. Challenges to HIV treatment adherence amongst adolescents in a low socio-economic setting in Cape Town. South Afr J HIV Med. 2019;20(1):1002. doi:10.4102/sajhivmed.v20i1.1002
Mutumba M, Musiime V, Lepkwoski JM, et al. Examining the relationship between psychological distress and adherence to anti-retroviral therapy among Ugandan adolescents living with HIV. AIDS Care. 2016;28(7):807-815. doi:10.1080/09540121.2015.1131966
Ryscavage P, Macharia T, Patel D, Palmeiro R, Tepper V. Linkage to and retention in care following healthcare transition from pediatric to adult HIV care. AIDS Care. 2016;28(5):561-565. doi:10.1080/09540121.2015.1131967
Griffith D, Jin L, Childs J, Posada R, Jao J, Agwu A. Outcomes of a comprehensive retention strategy for youth with HIV after transfer to adult care in the United States. Pediatr Infect Dis J. 2019;38(7):722-726. doi:10.1097/INF.0000000000002309
Castillo-Mancilla JR, Haberer JE. Adherence measurements in HIV: new advancements in pharmacologic methods and real-time monitoring. Curr HIV/AIDS Rep. 2018;15(1):49-59. doi:10.1007/s11904-018-0377-0
Onu DU. Treatment adherence mediates the relationship between HIV-related stigma and health-related quality of life. AIDS Care. 2021;33(10):1335-1339. doi:10.1080/09540121.2020.1867701
Haberer JE, Sabin L, Amico KR, et al. Improving antiretroviral therapy adherence in resource-limited settings at scale: a discussion of interventions and recommendations. J Int AIDS Soc. 2017;20(1):21371. doi:10.7448/IAS.20.1.21371
Makokha V, Ramadhani H, Amadi E, et al. Structured support through a return to care package to reduce lost to follow-up among patients on antiretroviral therapy in rural Western Kenya. Aids. 2020;23:937-938.
Tsutsumi T, Sato H, Kikuchi T, et al. Factors associated with clearance of hepatitis B virus surface antigen in patients infected with human immunodeficiency virus. Medicine. 2020;99(29):e21271. doi:10.1097/MD.0000000000021271
Bisallah CI, Ochigbo Onyilo M, Amali MA, et al. Effectiveness of dolutegravir (DTG), an HIV integrase inhibitorin improving viral load suppression among HIV infected treatment experienced patients in general hospital Minna, Nigeria. IOSR J Dent Med Sci e-ISSN. 2020;19(8):27-32. doi:10.9790/0853-1908082732